Gilead Sciences

GILD

NASDAQ·Health Care

Market Cap
-
P/E Ratio
-
Dividend Yield
-

Company Overview

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.

Industry
Biotechnology

Financial Summary

Revenue (TTM)
$22.13B
Net Income (TTM)
$4.59B
Total Assets
$62.13B
Total Debt
$24.99B
Total Equity
$22.83B
Market Cap
-

Valuation Metrics

P/E Ratio
-
P/B Ratio
-
Profit Margin
20.75%
ROE
20.11%
ROA
7.39%
Dividend Yield
-